Back to results
US 7,741,330 B1Granted
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
AssigneePharmacyclics, Inc.
InventorsWei Chen, David J. Loury, Tarak D. Mody
Life of this patent
Estimating the term…
Abstract
Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
Claims16
A compound having the structure of Formula (I):
- wherein:
- Ra, Rb, Rc, Rd and Re are each independently selected from H, F, Cl, Br, I, —CN, —SR2, —OR3, —CO2R3;
- or
- Ra or Rb together with one of Rc, Rd and Re and the carbon atoms to which they are attached form an epoxide;
- wherein Ra, Rb, Rc, Rd, and Re cannot all be H;
- R2 is selected from H, C1-C4alkyl, a cysteinyl, or a glutathionyl;
- R3 is selected from H, C1-C4alkyl, phenyl, or benzyl;
- or a pharmaceutically acceptable salt thereof.
5 more elements
A compound having the structure
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound having the structure of Formula (I):
- wherein:
- Ra, Rb, Rc, Rd and Re are each independently selected from H, F, Cl, Br, I, —CN, —SR2, —OR3, —CO2R3;
- or
- Ra or Rb together with one of Rc, Rd and Re and the carbon atoms to which they are attached form an epoxide;
- wherein Ra, Rb, Rc, Rd, and Re cannot all be H;
- R2 is selected from H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, a cysteinyl, or a glutathionyl;
- R3 is selected from H, C1-C4alkyl, phenyl, or benzyl;
- or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable excipient, binder or carrier.
6 more elements
Dependencies are inferred from the claim text.